We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Study Shows Advantages of New Prostate Cancer Treatment

By MedImaging International staff writers
Posted on 08 Aug 2017
Image: An example of brachytherapy treatment for prostate cancer patients (Photo courtesy of UCLA Health).
Image: An example of brachytherapy treatment for prostate cancer patients (Photo courtesy of UCLA Health).
A new study has shown that brachytherapy treatment of prostate cancer patients using the Cesium-131 Isotope provides a targeted, fast-acting treatment, within a 30-day delivery time, that is significantly better than other isotopes.

While many prostate cancer patients still undergo costly invasive surgery, or long-term radiation treatment, then new brachytherapy treatment could provide a more cost-effective and safer alternative with fewer side effects.

The study was published in the August 1, 2017, issue of the International Journal of Radiation Oncology, Biology and Physics. The researchers evaluated the long-term Quality of Life (QOL) scores reported by patients with prostate cancer, and showed that treatment using the newest brachytherapy isotope, Cesium-131, reduced the QOL and the length of the recovery period. The faster-acting Cesium-131 isotope is made by Isoray Medical (Richmond, WA, USA) and enables patients to recover faster from the radiation side effects, and return to normal bowel, urinary, and sexual function than those treated with other brachytherapy isotopes. Isoray uses a new proprietary process to manufacture the Cesium-131 brachytherapy isotope seeds.

Chicago Prostate Cancer Center medical director, Dr. Brian Moran, said, "For far too long, patients have been treated for prostate cancer based on a medical professionals' familiarity or, in some cases, due to far greater financial benefits to the physician. This study reinforces that a new, patient-friendly treatment exists. Brachytherapy with Cesium-131 leverages the isotope's short half-life to significantly reduce the duration of long-term symptoms and side effects."

Related Links:
Isoray Medical

New
High-Precision QA Tool
DEXA Phantom
New
Ultrasound Needle Guidance System
SonoSite L25
Silver Member
X-Ray QA Meter
T3 AD Pro
Radiology Software
DxWorks

Channels

Nuclear Medicine

view channel
Image: The prostate cancer imaging study aims to reduce the need for biopsies (Photo courtesy of Shutterstock)

New Imaging Approach Could Reduce Need for Biopsies to Monitor Prostate Cancer

Prostate cancer is the second leading cause of cancer-related death among men in the United States. However, the majority of older men diagnosed with prostate cancer have slow-growing, low-risk forms of... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.